Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, the Centers for ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Eli Lilly & Co. closed $199.24 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Though we’re well into the winter season, Lilly Pulitzer always finds a way to get us excited for spring and summer. The ...

Patricia Clarkson is forgettable in tonally confusing 'Lilly,' full of intrusively edited archival material and curious ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...